Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study
Abstract Background Type 1 gastric neuroendocrine tumors (NETs) are relatively rare to the extent that some physicians have little experience in diagnosing and treating them. The purpose of this study was to increase the understanding of the disease by analyzing and summarizing the management and pr...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-023-03079-6 |
| _version_ | 1797388299186208768 |
|---|---|
| author | Ying-Ying Chen Wen-Juan Guo Yan-Fen Shi Fei Su Fu-Huan Yu Ru-Ao Chen Chao Wang Ji-Xi Liu Jie Luo Huang-Ying Tan |
| author_facet | Ying-Ying Chen Wen-Juan Guo Yan-Fen Shi Fei Su Fu-Huan Yu Ru-Ao Chen Chao Wang Ji-Xi Liu Jie Luo Huang-Ying Tan |
| author_sort | Ying-Ying Chen |
| collection | DOAJ |
| description | Abstract Background Type 1 gastric neuroendocrine tumors (NETs) are relatively rare to the extent that some physicians have little experience in diagnosing and treating them. The purpose of this study was to increase the understanding of the disease by analyzing and summarizing the management and prognoses of patients with type 1 gastric NETs at our center. Methods The data of 229 patients (59.4% female) with type 1 gastric NETs who were treated at our center during 2011–2022 were retrospectively analyzed. Results The average patient age was 50.5 ± 10.8 years. Multiple tumors affected 72.5% of the patients; 66.4% of the tumors were < 1 cm, 69.4% were NET G1, and 2.2% were stage III-IV. A total of 76.9% of the patients had received endoscopic management, 60.7% had received traditional Chinese medicine treatment, 10.5% received somatostatin analogues treatment, and 6.6% underwent surgical resection. Seventy patients (41.2%) experienced the first recurrence after a median follow-up of 31 months (range: 2-122 months), and the median recurrence-free time was 43 months. The 1-, 2-, and 3-year cumulative recurrence-free survival rates were 71.8%, 56.8%, and 50.3%, respectively. During a median follow-up of 39 months (range: 2-132 months), one patient had bilateral pulmonary metastasis, and no disease-related deaths were observed. Conclusion Type 1 gastric NETs have a high recurrence rate and a long disease course, underscoring the importance of long-term and comprehensive management. |
| first_indexed | 2024-03-08T22:38:50Z |
| format | Article |
| id | doaj.art-db0a35dd74eb486db00977c3a81e40cc |
| institution | Directory Open Access Journal |
| issn | 1471-230X |
| language | English |
| last_indexed | 2024-03-08T22:38:50Z |
| publishDate | 2023-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj.art-db0a35dd74eb486db00977c3a81e40cc2023-12-17T12:19:30ZengBMCBMC Gastroenterology1471-230X2023-12-0123111010.1186/s12876-023-03079-6Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center studyYing-Ying Chen0Wen-Juan Guo1Yan-Fen Shi2Fei Su3Fu-Huan Yu4Ru-Ao Chen5Chao Wang6Ji-Xi Liu7Jie Luo8Huang-Ying Tan9Beijing University of Chinese MedicineDepartment of Gastroenterology, China-Japan Friendship HospitalDepartment of Pathology, China-Japan Friendship HospitalDepartment of Integrative Oncology, China-Japan Friendship HospitalBeijing University of Chinese MedicineBeijing University of Chinese MedicineDepartment of Integrative Oncology, China-Japan Friendship HospitalDigestive Disease Center, Beijing United Family HospitalDepartment of Pathology, China-Japan Friendship HospitalDepartment of Integrative Oncology, China-Japan Friendship HospitalAbstract Background Type 1 gastric neuroendocrine tumors (NETs) are relatively rare to the extent that some physicians have little experience in diagnosing and treating them. The purpose of this study was to increase the understanding of the disease by analyzing and summarizing the management and prognoses of patients with type 1 gastric NETs at our center. Methods The data of 229 patients (59.4% female) with type 1 gastric NETs who were treated at our center during 2011–2022 were retrospectively analyzed. Results The average patient age was 50.5 ± 10.8 years. Multiple tumors affected 72.5% of the patients; 66.4% of the tumors were < 1 cm, 69.4% were NET G1, and 2.2% were stage III-IV. A total of 76.9% of the patients had received endoscopic management, 60.7% had received traditional Chinese medicine treatment, 10.5% received somatostatin analogues treatment, and 6.6% underwent surgical resection. Seventy patients (41.2%) experienced the first recurrence after a median follow-up of 31 months (range: 2-122 months), and the median recurrence-free time was 43 months. The 1-, 2-, and 3-year cumulative recurrence-free survival rates were 71.8%, 56.8%, and 50.3%, respectively. During a median follow-up of 39 months (range: 2-132 months), one patient had bilateral pulmonary metastasis, and no disease-related deaths were observed. Conclusion Type 1 gastric NETs have a high recurrence rate and a long disease course, underscoring the importance of long-term and comprehensive management.https://doi.org/10.1186/s12876-023-03079-6Type 1 gastric neuroendocrine tumorsManagementRecurrencePrognosis |
| spellingShingle | Ying-Ying Chen Wen-Juan Guo Yan-Fen Shi Fei Su Fu-Huan Yu Ru-Ao Chen Chao Wang Ji-Xi Liu Jie Luo Huang-Ying Tan Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study BMC Gastroenterology Type 1 gastric neuroendocrine tumors Management Recurrence Prognosis |
| title | Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study |
| title_full | Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study |
| title_fullStr | Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study |
| title_full_unstemmed | Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study |
| title_short | Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study |
| title_sort | management of type 1 gastric neuroendocrine tumors an 11 year retrospective single center study |
| topic | Type 1 gastric neuroendocrine tumors Management Recurrence Prognosis |
| url | https://doi.org/10.1186/s12876-023-03079-6 |
| work_keys_str_mv | AT yingyingchen managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT wenjuanguo managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT yanfenshi managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT feisu managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT fuhuanyu managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT ruaochen managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT chaowang managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT jixiliu managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT jieluo managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy AT huangyingtan managementoftype1gastricneuroendocrinetumorsan11yearretrospectivesinglecenterstudy |